Welcome!

News Feed Item

Stammering Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Stammering Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280948/Stammering-Global-Clinical-Trials-Review-H2-2014.html

Stammering Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Stammering Global Clinical Trials Review, H2, 2014" provides data on the Stammering clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Stammering. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Stammering. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Stammering 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Stammering to Central Nervous System Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Stammering to Central Nervous System Clinical Trials 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Unaccomplished Trials of Stammering 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Clinical Trial Profiles 25
Clinical Trial Overview of Top Companies 25
Endo International plc 25
Clinical Trial Overview of Endo International plc 25
Clinical Trial Overview of Top Institutes / Government 26
National Institute on Deafness and Other Communication Disorders 26
Clinical Trial Overview of National Institute on Deafness and Other Communication Disorders 26
National Institute of Neurological Disorders and Stroke 27
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 27
The University of Sydney 28
Clinical Trial Overview of The University of Sydney 28
Tbilisi State Medical University 29
Clinical Trial Overview of Tbilisi State Medical University 29
Universidade Federal de Minas Gerais 30
Clinical Trial Overview of Universidade Federal de Minas Gerais 30
Pharmacology Research Institute 31
Clinical Trial Overview of Pharmacology Research Institute 31
The Newcastle upon Tyne Hospitals NHS Foundation Trust 32
Clinical Trial Overview of The Newcastle upon Tyne Hospitals NHS Foundation Trust 32
Universitatsklinikum Munster 33
Clinical Trial Overview of Universitatsklinikum Munster 33
University of California, Irvine 34
Clinical Trial Overview of University of California, Irvine 34
Five Key Clinical Profiles 35
Appendix 50
Abbreviations 50
Definitions 50
Research Methodology 51
Secondary Research 51
About GlobalData 52
Contact Us 52
Disclaimer 52
Source 52

List of Tables

Stammering Therapeutics, Global, Clinical Trials by Region, 2014* 6
Stammering Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Stammering Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Stammering Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Stammering Therapeutics Clinical Trials, Europe, Top Countries, 2014* 10
Stammering Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Stammering Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 12
Proportion of Stammering to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Stammering Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Stammering Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Stammering to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Stammering Therapeutics, Global, Clinical Trials by Phase, 2014* 17
Stammering Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 18
Stammering Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Stammering Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Stammering Therapeutics, Global, Suspended Clinical Trials, 2014* 21
Stammering Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Stammering Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 23
Stammering Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Endo International plc, 2014* 25
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute on Deafness and Other Communication Disorders, 2014* 26
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 27
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Sydney, 2014* 28
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Tbilisi State Medical University, 2014* 29
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Universidade Federal de Minas Gerais, 2014* 30
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacology Research Institute, 2014* 31
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by The Newcastle upon Tyne Hospitals NHS Foundation Trust, 2014* 32
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by Universitatsklinikum Munster, 2014* 33
Stammering Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Irvine, 2014* 34

List of Figures

Stammering Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Stammering Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Stammering Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Stammering Therapeutics Clinical Trials, Europe, Top Countries (%), 2014* 10
Stammering Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Proportion of Stammering to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Stammering Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Stammering Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Stammering to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Stammering Therapeutics, Global, Clinical Trials by Phase (%), 2014* 17
Stammering Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 18
Stammering Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Stammering Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Stammering Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 23
GlobalData Methodology 51

To order this report: Stammering Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280948/Stammering-Global-Clinical-Trials-Review-H2-2014.html

_________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
IoT solutions exploit operational data generated by Internet-connected smart “things” for the purpose of gaining operational insight and producing “better outcomes” (for example, create new business models, eliminate unscheduled maintenance, etc.). The explosive proliferation of IoT solutions will result in an exponential growth in the volume of IoT data, precipitating significant Information Governance issues: who owns the IoT data, what are the rights/duties of IoT solutions adopters towards t...
Regulatory requirements exist to promote the controlled sharing of information, while protecting the privacy and/or security of the information. Regulations for each type of information have their own set of rules, policies, and guidelines. Cloud Service Providers (CSP) are faced with increasing demand for services at decreasing prices. Demonstrating and maintaining compliance with regulations is a nontrivial task and doing so against numerous sets of regulatory requirements can be daunting task...
"We are a modern development application platform and we have a suite of products that allow you to application release automation, we do version control, and we do application life cycle management," explained Flint Brenton, CEO of CollabNet, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Dataloop.IO, an innovator in cloud IT-monitoring whose products help organizations save time and money, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Dataloop.IO is an emerging software company on the cutting edge of major IT-infrastructure trends including cloud computing and microservices. The company, founded in the UK but now based in San Fran...
Application transformation and DevOps practices are two sides of the same coin. Enterprises that want to capture value faster, need to deliver value faster – time value of money principle. To do that enterprises need to build cloud-native apps as microservices by empowering teams to build, ship, and run in production. In his session at @DevOpsSummit at 19th Cloud Expo, Neil Gehani, senior product manager at HPE, discussed what every business should plan for how to structure their teams to delive...
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Phil Hombledal, Solution Architect at CollabNet, discussed how customers are able to achieve a level of transparency that e...
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
CloudJumper, a Workspace as a Service (WaaS) platform innovator for agile business IT, has been recognized with the Customer Value Leadership Award for its nWorkSpace platform by Frost & Sullivan. The company was also featured in a new report(1) by the industry research firm titled, “Desktop-as-a-Service Buyer’s Guide, 2016,” which provides a comprehensive comparison of DaaS providers, including CloudJumper, Amazon, VMware, and Microsoft.
SYS-CON Events announced today that Fusion, a leading provider of cloud services, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Fusion, a leading provider of integrated cloud solutions to small, medium and large businesses, is the industry’s single source for the cloud. Fusion’s advanced, proprietary cloud service platform enables the integration of leading edge solutions in the cloud, including clou...
Unsecured IoT devices were used to launch crippling DDOS attacks in October 2016, targeting services such as Twitter, Spotify, and GitHub. Subsequent testimony to Congress about potential attacks on office buildings, schools, and hospitals raised the possibility for the IoT to harm and even kill people. What should be done? Does the government need to intervene? This panel at @ThingExpo New York brings together leading IoT and security experts to discuss this very serious topic.
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service. In his session at 19th Cloud Exp...
Fact: storage performance problems have only gotten more complicated, as applications not only have become largely virtualized, but also have moved to cloud-based infrastructures. Storage performance in virtualized environments isn’t just about IOPS anymore. Instead, you need to guarantee performance for individual VMs, helping applications maintain performance as the number of VMs continues to go up in real time. In his session at Cloud Expo, Dhiraj Sehgal, Product and Marketing at Tintri, sha...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life sett...
Much of the value of DevOps comes from a (renewed) focus on measurement, sharing, and continuous feedback loops. In increasingly complex DevOps workflows and environments, and especially in larger, regulated, or more crystallized organizations, these core concepts become even more critical. In his session at @DevOpsSummit at 18th Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, showed how, by focusing on 'metrics that matter,' you can provide objective, transparent, and meaningful f...